Li Xueying, Kang Qianyan, Gao Shan, Wei Ting, Liu Yong, Chen Xinlin, Lv Haixia
Department of Ophthalmology, The First Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Department of Ophthalmology, The First Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Neurosci Lett. 2014 Jan 13;558:8-13. doi: 10.1016/j.neulet.2013.09.024. Epub 2013 Sep 25.
The retinal ischemia-reperfusion injury (RIR) is a common pathological process that leads to progressive visual loss and blindness in many retinal diseases such as retinal vascular occlusion disease, diabetic retinopathy, and acute glaucoma. Currently, there has been no effective therapy. The purpose of this study was to investigate the effects of transplantation of retinal progenitor cells (RPCs) into the subretinal space (SRS) and the superior colliculus (SC) in a rat model of RIR injury. We used cultured postnatal day 1 rat RPCs transfected with adeno-associated virus containing the cDNA encoding enhanced green fluorescence protein (EGFP) for transplantation. RIR injury was induced by increases in the intraocular pressure to 110 mmHg for 60 min. The effects of transplantation were evaluated by immunohistochemistry, electroretinography (ERG), and visual evoked potentials (VEP). We found that in rats with RIR injury, RPCs transplanted into the SRS and the SC survived for at least 8 weeks, migrated into surrounding tissues, and improved the ERG and VEP responses. Cells transplanted into the SC improved the VEP response more than those transplanted into the SRS. Our data suggest that transplantation of RPCs into the SRS and the SC may be a possible method for cell replacement therapy for retinal diseases.
视网膜缺血再灌注损伤（RIR）是一种常见的病理过程，在许多视网膜疾病如视网膜血管阻塞性疾病、糖尿病视网膜病变和急性青光眼等中会导致进行性视力丧失和失明。目前，尚无有效的治疗方法。本研究的目的是在RIR损伤大鼠模型中，研究将视网膜祖细胞（RPCs）移植到视网膜下间隙（SRS）和上丘（SC）的效果。我们使用用携带编码增强型绿色荧光蛋白（EGFP）的cDNA的腺相关病毒转染的出生后第1天大鼠培养RPCs进行移植。通过将眼压升高至110 mmHg持续60分钟诱导RIR损伤。通过免疫组织化学、视网膜电图（ERG）和视觉诱发电位（VEP）评估移植效果。我们发现，在RIR损伤的大鼠中，移植到SRS和SC的RPCs至少存活8周，迁移到周围组织，并改善了ERG和VEP反应。移植到SC的细胞比移植到SRS的细胞对VEP反应的改善更大。我们的数据表明，将RPCs移植到SRS和SC可能是视网膜疾病细胞替代治疗的一种可行方法。
